Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171015 | 0.89 | NPC1 (0.65) | NPC1POLBTSHRSYKALDH1A1 | |
| SCHEMBL14421921 | 0.87 | TDP1 (0.56) | NPC1POLBTSHRKDM4EHTT | |
| SCHEMBL13648207 | 0.85 | NPC1 (0.61) | NPC1POLBTSHRSYKHSP90AA1 | |
| SCHEMBL14420826 | 0.82 | POLB (0.67) | NPC1POLBTSHRSYKALDH1A1 | |
| SCHEMBL23239917 | 0.82 | POLB (0.75) | NPC1POLBTSHRSYKHSP90AA1 | |
| SCHEMBL13648168 | 0.80 | ALDH1A1 (0.56) | NPC1POLBTSHRALDH1A1KDM4E | |
| SCHEMBL14420763 | 0.78 | POLB (1.00) | NPC1POLBTSHRSYKALDH1A1 | |
| SCHEMBL21276817 | 0.78 | TSHR (0.65) | NPC1POLBTSHRHSP90AA1HSP90AB1 | |
| SCHEMBL12856503 | 0.77 | NPC1 (0.58) | NPC1POLBTSHRSYKALDH1A1 | |
| SCHEMBL14578278 | 0.77 | LTA4H (0.70) | NPC1POLBTSHRSYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | NPC1 2476/4885POLB 1683/4885TSHR 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.